IL1B and myocardial infarction: This landmark study provided hitherto undocumented evidence that anti-inflammatory drugs targeting interleukin-1β (IL-1β) (canazumab) could effectively reduce the incidence of cardiovascular adverse events in patients with myocardial infarction, even when combined with lipid-lowering drugs.